ACXP logo

ACURX PHARMACEUTICALS INC

ACXPNASDAQ
๐Ÿ† #4909 by market capUS Equity
$1.03โ–ฒ $0.00 (+0.00%)
Market closed ยท at close
๐Ÿ””
Track ACXP
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ฒ 0.0%
7dโ–ฒ 8.4%
14dโ–ผ 3.3%
30dโ–ผ 11.2%
ytdโ–ผ 62.5%
1yโ–ผ 75.7%
๐ŸฆMarket Cap
$6M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
โ€”
๐Ÿ“ŠGross Margin
โ€”
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
โ€”
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$1.03 โ€“ $1.09
52-Week Range
$0.90 โ€“ $7.54
Volume (shares)
1,299
Avg Volume (shares)
โ€”
Shares Outstanding
5.6M
Next Earnings
โ€”

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
โ€”
P/S Ratio
โ€”
EPS (TTM)
$-3.10
Dividend Yield
โ€”
ACXP logo

ACURX PHARMACEUTICALS INC

ACXP
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About ACURX PHARMACEUTICALS INC

Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.